

Resource Summary Report

Generated by NIF on Jul 29, 2026

CD33-APC, human

RRID:AB_2660349

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-098-864, RRID:AB_2660349

Antibody Information

URL: http://antibodyregistry.org/AB_2660349

Proper Citation: Miltenyi Biotec Cat# 130-098-864, RRID:AB_2660349

Target Antigen: CD33

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 2-2018; Target Distribution basophils, dendritic cells, granulocytes, Langerhans cells, leukemia cells, macrophages, mast cells, monocytes, myeloid cells, NK cells, T cells; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-907. (RRID:AB_2726397).

Antibody Name: CD33-APC, human

Description: This monoclonal targets CD33

Target Organism: non-human primate, human

Clone ID: AC104.3E3

Antibody ID: AB_2660349

Vendor: Miltenyi Biotec

Catalog Number: 130-098-864

Record Creation Time: 20250820T000306+0000

Record Last Update: 20250820T071351+0000

Ratings and Alerts

No rating or validation information has been found for CD33-APC, human.

Warning: Discontinued: 2021

Discontinued: 2-2018; Target Distribution basophils, dendritic cells, granulocytes, Langerhans cells, leukemia cells, macrophages, mast cells, monocytes, myeloid cells, NK cells, T cells; target type CD markers; tested applications MACS Flow Cytometry; quantity: Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-907. (RRID:AB_2726397).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Perna F, et al. (2017) Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML. Cancer cell, 32(4), 506.